BPTH
Bio-Path Holdings, Inc.
Set alert
- YTD
- -99.50%
- 1 year
- -99.67%
- Open
- 0.0001
- Prev close
- 0.0003
- Mkt cap
- 15.09K
- Vol
- 104
- Avg vol
- 33.73K
- EPS
- -1.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.26
- Beta
- 0.22
- Short ratio
- 0.03
- Inst. own
- 1.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 8, 2024
- 50-d avg
- 0.8966
- 200-d avg
- 1.90
- 1y target
- 12.00
Key statistics
- Market cap
- 4.48M
- Enterprise value
- -1.88M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.46
- EPS (TTM)
- -8.34
- Beta
- 0.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.87M
- Total cash
- 4.01M
- Total debt
- 55.00K
- Return on equity
- -366.18%
- Shares outstanding
- 4.31M
- Short % of float
- 2.10%
- 50-day average
- 0.8966
- 200-day average
- 1.90
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 8, 2024
Expected Mar 8, 2024. Consensus EPS estimate -0.37.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -1.02 | -0.87 | +0.15 | +14.71% |
| Aug 15, 2024 | Jun 1, 2024 | -1.54 | -1.16 | +0.38 | +24.68% |
| May 15, 2024 | Mar 1, 2024 | -4.54 | -4.88 | -0.34 | -7.49% |
| Mar 8, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 15, 2023 | Sep 1, 2023 | -6.80 | -6.40 | +0.40 | +5.88% |
| Aug 15, 2023 | Jun 1, 2023 | -10.40 | -10.60 | -0.20 | -1.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2024 | Roth MKM | reit | Buy | Buy |
| Apr 18, 2024 | Roth MKM | reit | Buy | Buy |
| Mar 27, 2024 | Roth MKM | main | Buy | Buy |
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biopathholdings.com
News
- Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)
- Critical Analysis: Amarillo Biosciences (OTCMKTS:AMAR) vs. Bio-Path (NASDAQ:BPTH)
- Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
- Bio-Path Holdings Provides Clinical and Operational Update
- Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
- Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
- Bio-Path Holdings Reports Full Year 2024 Financial Results
- Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
- US Stocks Mixed; NY State Business Activity Rises In February
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on BPTH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.32% | 13,598 | 14.14K | Sep 29, 2024 |
| Vanguard Group Inc | 0.31% | 13,502 | 14.04K | Sep 29, 2024 |
| Virtu Financial LLC | 0.29% | 12,325 | 12.82K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.25% | 10,917 | 11.35K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 3,371 | 3.50K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 2,856 | 2.97K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.31% | 13,502 | 14.04K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.28% | 11,963 | 12.44K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 485 | 504 | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 1 | 1 | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 170 | 176 | Oct 30, 2024 |